Ipilimumab, Pembrolizumab and Nivolumab being used in melanoma treatment target:
a) Natural Killer cells
b) T-cell activating receptors
c) T-cell inhibitory receptors
d) B-cells
Ipilimumab, Pembrolizumab and Nivolumab being used in melanoma treatment target:
a) Natural Killer cells
b) T-cell activating receptors
c) T-cell inhibitory receptors
d) B-cells